Business
Ardelyx Announces Four Tenapanor Presentations at ASN's Kidney Week 2021
Data to provide insights on long term safety and efficacy of tenapanor in controlling serum phosphorus in patients with CKD on dialysis FREMONT, Calif. and
About this update from Ardelyx, Inc.
[{"type":"text","content":"Data to provide insights on long term safety and efficacy of tenapanor in controlling serum phosphorus in patients with CKD on dialysis\n\n\nFREMONT, Calif. and WALTHAM, Mass., Oct. 29, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that four tenapanor abstracts have been accepted for presentation at the American Society of Nephrology Kidney Week 2021 (ASN Kidney Week), which is taking place virtually November 4 - November 7, 2021. The accepted abstracts present new observations for tenapanor, a first-in-class phosphate absorption inhibitor which has completed three successful Phase 3 clinical trials for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis. Tenapanor was discovered and developed by Ardelyx.\n\n \n \n \n \n \n \n\n \nInformation regarding ASN Kidney Week, including the abstracts listed below are available on the conference website at https://www.asn-online.org/education/kidneyweek/\nArdelyx Poster Presentations: Title: Impact of Tenapanor in Peritoneal DialysisAbstract Number: PO0544Date/Time: November 04, 2021, 10:00 AM-12:00 PM\nTitle: Tenapanor Controls Serum Phosphorus and Reduces PTH and FGF-23 in Patients on Dialysis with Severe Secondary HyperparathyroidismAbstract Number: TH-OR18Date/Time: November 04, 2021, 4:30 PM-6:30 PM\nTitle: Long-Term Safety of Tenapanor for the Control of Serum Phosphorus in Patients with CKD on Dialysis: Serum Electrolytes and AlbuminAbstract Number: PO1732Date/Time: November 04, 2021, 10:00 AM-12:00 PM\nTitle: Patient-Reported Experience with Tenapanor in the OPTIMIZE TrialAbstract Number: PO1733Date/Time: November 04, 2021, 10:00 AM-12:00 PM\nAbout Ardelyx, IncArdelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, ...